revenue $0, net income -$12.8M. Moleculin omits controls disclosure, faces Nasdaq delisting risk after 2025 compliance lapses

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

• high

  Current 10-Q contains no disclosure controls or internal controls section, whereas prior filing certified both as effective. Absence of required controls evaluation raises governance and compliance concerns.

  Controls & Procedures verify on EDGAR →
• high

  Company received Nasdaq non-compliance notices in 2025 for failing minimum equity ($2.5M) and bid price ($1.00) requirements. Compliance regained by early 2026, but warns future delisting could severely impact liquidity and capital access.

  Risk Factors: Nasdaq Delisting verify on EDGAR →
• high

  MIRACLE trial interim unblinding delayed from end-2025 to mid-2026, but blinded data from first 45 patients shows 40%+ composite complete remission vs 17-18% historical cytarabine-alone rates. 56 subjects enrolled (62% of Part A target).

  MD&A: MIRACLE Trial Progress verify on EDGAR →